TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the United States Patent and Trademark Office (“USPTO”) has granted U.S.

。

patent 12,122,741 (‘741) with claims to the composition of matter of lead preclinical candidates in the Company's CYB005 phenethylamines program..

专利12122741（'741），要求保护该公司CYB005苯乙胺计划中主要临床前候选药物的物质组成。。

The Company is investigating novel molecules within the CYB005 program at non-hallucinogenic doses for a range of Central Nervous System (“CNS”) disorders. In addition, the Company is continuing to explore non-hallucinogenic neuroplastogens within its broader discovery pipeline, as well as targeted serotonin 5-HT1A and 5-HT2C receptor agonists..

该公司正在研究CYB005计划中针对一系列中枢神经系统（“CNS”）疾病的非致幻剂剂量的新型分子。此外，该公司正在其更广泛的发现渠道中继续探索非致幻剂神经塑化剂，以及靶向血清素5-HT1A和5-HT2C受体激动剂。。

“The granting of this patent in support of our CYB005 phenethylamines program reinforces our commitment to expanding the breadth of innovative development work beyond our clinical tryptamine programs,” said Doug Drysdale, Chief Executive Officer of Cybin. “Non-hallucinogenic 5-HT receptor agonists have garnered a great deal of attention in recent years, and we are eager to continue exploring their clinical potential in CNS disorders.

Cybin首席执行官道格·德赖斯代尔（DougDrysdale）表示：“这项专利的授予支持了我们的CYB005苯乙胺项目，加强了我们在临床色胺项目之外扩大创新开发工作广度的承诺。非致幻剂5-HT受体激动剂近年来备受关注，我们渴望继续探索其在中枢神经系统疾病中的临床潜力。

While our primary focus remains on our clinical-stage psychiatry programs, CYB003 and CYB004, we believe that other programs like CYB005 that target CNS disorders have the potential to address significant unmet medical needs. We remain focused on demonstrating our scientific leadership in the space, while delivering long-term shareholder value.”.

虽然我们的主要重点仍然是我们的临床阶段精神病学计划CYB003和CYB004，但我们相信针对中枢神经系统疾病的其他计划（如CYB005）有可能解决严重未满足的医疗需求。我们仍然专注于展示我们在该领域的科学领导力，同时为股东带来长期价值。”。

The Company previously announced that its research manuscript, entitled “Synthesis and Structure-Activity Relationships of 2,5-dimethoxy-4-substituted phenethylamines and the discovery of CYB210010: A potent, orally bioavailable and long-acting serotonin 5-HT2 receptor agonist,” was published in the Journal of Medicinal Chemistry, a prestigious bi-weekly peer-reviewed publication of the American Chemical Society..

该公司之前宣布，其研究手稿题为“2,5-二甲氧基-4-取代苯乙胺的合成和构效关系以及CYB210010的发现：一种有效的，口服生物可利用的长效血清素5-HT2受体激动剂”，发表在《药物化学杂志》上，该杂志是美国化学学会著名的每两周一次的同行评审出版物。。

About Cybin

关于Cybin

Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.

Cybin是一家后期突破性的神经精神病学公司，致力于通过开发新的和创新的下一代治疗方案来彻底改变精神保健，以解决精神健康状况患者的大量未满足需求。

With industry leading proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin program, about to enter Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated DMT program in a Phase 2 study for generalized anxiety disorder.

凭借业界领先的概念验证数据，Cybin正在通过引入间歇性治疗来改变心理健康治疗的格局，从而提供持久的结果。该公司目前正在开发CYB003，一种专有的氘化裸盖菇素计划，即将进入辅助治疗重度抑郁症的3期研究和CYB004，CYB004是一种专有的氘化DMT计划，用于广泛性焦虑症的2期研究。

The company also has a research pipeline of investigational, 5-HT-receptor focused compounds..

该公司还拥有以5-HT受体为重点的研究性化合物的研究渠道。。

Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.

Cybin成立于2019年，在加拿大、美国、英国、荷兰和爱尔兰运营。有关Cybin的公司更新和更多信息，请访问www.Cybin.com或在X、LinkedIn、YouTube和Instagram上关注团队。

Cautionary Notes and Forward-Looking Statements

Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements.

本新闻稿中有关公司的某些声明是前瞻性声明，具有前瞻性。前瞻性陈述并非基于历史事实，而是基于当前对未来事件的预期和预测，因此存在风险和不确定性，可能导致实际结果与前瞻性陈述所表达或暗示的未来结果存在重大差异。

These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s belief that CYB005 has the potential to address significant unmet medical needs; and the Company’s proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders..

这些陈述通常可以通过使用前瞻性词语来识别，例如“可能”、“应该”、“可能”、“打算”、“估计”、“计划”、“预期”、“期望”、“相信”或“继续”，或其负面或类似的变化。本新闻稿中的前瞻性声明包括关于公司相信CYB005有潜力解决重大未满足医疗需求的声明；以及该公司专有的药物发现平台，创新的药物输送系统，新颖的配方方法和精神健康障碍的治疗方案。。

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements.

这些前瞻性陈述是基于做出此类陈述时公司管理层的合理假设和估计。由于前瞻性陈述涉及已知和未知的风险、不确定性和其他因素，可能导致公司的实际结果、业绩或成就与此类前瞻性陈述中明示或暗示的任何未来结果、业绩或成就存在重大差异，因此未来的实际结果可能会产生重大差异。

Such factors, among other things, include: implications of the spread of COVID-19 on the Company's operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in each of the Company's management's discussion and analysis for the three months ended June 30, 2024 and the Company’s annual information form for the year ended March 31, 2024, which are available under the Company's profile on www.sedarplus.ca and with the U.S.

除其他因素外，这些因素包括：新型冠状病毒传播对公司运营的影响；总体宏观经济状况的波动；证券市场波动；对迷幻药市场规模的期望；公司成功实现其业务目标的能力；增长计划；政治、社会和环境不确定性；员工关系；存在可能对公司经营所在市场施加限制的法律法规；以及截至2024年6月30日的三个月内公司管理层的讨论和分析以及截至2024年3月31日的公司年度信息表中列出的风险因素，这些信息可在www.sedarplus.ca和美国的公司简介中找到。

Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended.

尽管本新闻稿中的前瞻性陈述是基于公司管理层认为或当时认为的合理假设，但公司无法向股东保证实际结果与此类前瞻性陈述一致，因为可能存在其他因素导致结果不符合预期、估计或预期。

Readers should .

读者应该。

Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds.

Cybin没有就Cybin的拟议产品提出任何医疗、治疗或健康福利要求。美国食品和药物管理局、加拿大卫生部或其他类似监管机构尚未评估有关裸盖菇素、迷幻色胺、色胺衍生物或其他迷幻化合物的索赔。

The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed.

此类产品的功效尚未得到批准研究的证实。不能保证使用裸盖菇素、迷幻色胺、色胺衍生物或其他迷幻化合物可以诊断、治疗、治愈或预防任何疾病或病症。需要严格的科学研究和临床试验。

Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin’s performance and operations..

Cybin尚未对其拟议产品的使用进行临床试验。。如果Cybin无法获得商业化业务所需的批准或研究，可能会对Cybin的业绩和运营产生重大不利影响。。

Neither the Cboe Canada nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.

加拿大芝加哥期权交易所（Cboe Canada）和纽约证券交易所（NYSE American LLC stock exchange）均未批准或不批准本新闻稿的内容，对本新闻稿内容的充分性和准确性概不负责。